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Abstract
Background: Percutaneous carotid artery stenting (CAS) became a widely used procedure in patients with symptomatic and
asymptomatic carotid artery stenosis. However its role compared to carotid endarterectomy (CAD) remains questioned. We
analysed the safety of carotid artery stenting program of a prospective CAS register program of a tertiary teaching hospital.
Method: Between July 2003 and December 2010, 208 patients underwent CAS procedure. Baseline, procedural and follow-
up data were prospectively collected. Primary peri-interventional outcome was defined as 30-day major adverse events
(MAE), including death, stroke or myocardial infarction, and mid- to long-term follow-up outcome included ipsilateral stroke,
myocardial infarction or death. Secondary outcome was restenosis rate $50% per lesion.
Results: Unilateral carotid artery interventions were performed in 186 patients. In 22 patients CAS was performed bilaterally
as stages procedures. The 30-day MAE rate was 1.9% consisting of two contralateral strokes and two ipsilateral stroke. Mean
clinically follow-up was 22 months. Mid- to long-term MAE was 8.1% with 6.3% (n=13) deaths, 1.9% (n=4) myocardial
infarctions and 0.9% (n=2) ipsilateral stroke. The restenosis rate $50% per lesion was 4.3% at a mean follow-up of
22 months. Target lesion revascularization was performed in one patient, because of restenosis at 9 months follow-up after
first CAS.
Conclusion: Implementation of a carotid artery stenting program at a tertiary, teaching hospital is a safe method for
treatment of carotid artery stenosis. The adverse event rate during mid-to-long-term follow-up suggests an appropriate
patient selection.
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Introduction
Stroke is one of the leading causes of death following
ischemic heart disease and is one of the most frequent reasons
of permanent disability [1]. It has been estimated that
significant stenosis of the internal carotid artery may be the
predisposing condition in 5–12% of all strokes [2]. Carotid
endarterectomy has been shown to reduce the risk of recurrent
stroke by a half in patients with recent cerebrovascular
symptoms associated with severe carotid stenosis [3]. Endovas-
cular treatment of carotid stenosis by percutaneous transluminal
balloon angioplasty or insertion of a stent is an accepted
alternative to endarterectomy [4]. However, a meta-analysis
(2007) found a higher risk of stroke or death within 30 days
after endovascular treatment than after endarterectomy, and
endarterectomy has remained the treatment of choice for
carotid stenosis [5]. In addition, current results from the
CAVATAS study show that restenosis is more common after
endovascular treatment than after endarterectomy and is
associated with recurrent ipsilateral cerebrovascular symptoms
but that the risk of recurrent ipsilateral stroke is low [6].
In contrast, studies such as the Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomie trial
(SAPPHIRE) suggested that CAS may have a better outcome than
CEA in selected patients [7]. The SPACE trial (stent protected
angioplasty versus carotid endarterectomy) failed to prove the non-
inferiority of CAS for the 30-day complication rate but showed
similar results at two years follow-up [8]. The EVA-3S trial
(endarterectomy versus angioplasty in patients with severe
symptomatic stenosis) even showed significant higher rates of
death and stroke within 30 days in CAS compared to CEA [9]. In
summary, all results from randomized trials the optimal role of
carotid angioplasty/stenting versus endarterectomy remains un-
clear. While the EVA-3S trial has been criticized for the limited
interventional experience requested for participation in the study
[9], consensus on minimal training requirements and performance
data of newly initiated CAS programs are lacking. Recently we
reported on the safety of starting a carotid stenting program in 100
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efficacy and safety of carotid stenting program in a larger series of
patients at a tertiary referral and teaching center.
Methods
Carotid Stenting Program and Patient Selection
Our registry included 229 consecutive patients who underwent
carotid artery stenting (CAS) from July 2003 until December 2010.
In 7 patients undergoing diagnostic angiography the revascular-
ization procedure was not performed because of absence of severe
stenosis (n=5) and carotid artery occlusion (n=2), respectively. In
addition, in another 3 patients CAS was not performed because of
severe vessel tortuosity and hence inaccessible carotid artery and
thereafter referred for carotid endarterectomy. In all 10 patients
the procedure was stopped without any neurologic or cardiovas-
cular complications. 11 patients (5.3%) were excluded due to an
incomplete follow-up, 208 patients remained for analysis. Patient
characteristics are summarized in table 1. Interventional physician
experience following a CAS-fellowship-training includes minimally
100 diagnostic cerebral angiographies and 40 CAS procedures
performed as first or second operator during under supervision by
an experienced interventional physician. The CAS interventions
in our case series have been done by 2 Cardiologists with high
volume caseload in coronary interventions. Their experience in
working with 0.014’’ wires and guiding catheters is higher than
optimal requested by guidelines. The caseload was each year
higher, starting by 5 cases 2003, and ending by 48 cases 2010.
Patients were considered for revascularization in the presence of
a $70% asymptomatic or a $50% symptomatic stenosis of the
internal carotid artery (Fig. 1).
Stenosis was considered symptomatic in the presence of
transient ischemic attack or stroke affecting the corresponding
territory in the preceding 6 months. Stenosis severity was assessed
by color-coded duplexsonography (CCDS) and either confirmed
by CT or MR angiography. In all patients a baseline imaging of
the brain with CT or MR was performed. The indication for
revascularization was approved by a neurologist in all cases (US).
The neurologist examined all patients before and after the
procedure. ECG and creatinin kinase (CK), CK-MB, and
troponin were obtained systematically on admission and the day
after CAS.
Written informed consent was obtained from all patients
enrolled in the study. The present study was approved by the
institutional review board (Cantonal Ethics Committee) of Zurich,
Switzerland.
Technique
All patients were pre-treated with aspirin and clopidogrel and
during the procedure unfractionated heparin was administered to
achieve an activated clotting time of 250–300 sec. Four-vessel
angiography, consisting of at least a selective angiography of both
common carotid arteries and a nonselective angiography of the
subclavian and vertebral arteries, was performed using 5F
diagnostic catheter unless contraindicated (e.g., in the presence
of renal insufficiency, severe calcification or tortuosity of the aortic
arch or the supraaortic vessels). Digital subtraction angiography of
each vessel was obtained at the cervical and intracranial level. The
stenting procedure was performed wih either a 8F guiding catheter
advanced over a 125 cm-long 5F diagnostic catheter with
telescoping technique or a 6F 90 cm-long sheath (Fig. 2).
All procedures were attempted to be performed with proximal
or distal protection devices that was at the discretion of the
interventional physician and vascular conditions. To prevent
Table 1. Baseline Characteristics.
n=208
Age, gender
Mean age, years 69
Range age, years 38–88
Age . 70 years, n (%) 65 (31)
male gender, n (%) 146 (70)
Cardiovascular risk factors, n (%)
Diabetes mellitus 63 (30)
Dislipida ¨mia 162 (78)
Hypertension 178 (86)
Current smoking 76 (36)
History of cardiovascular disease, n (%)
Previous PCI 108 (52)
Previous CAGB 96 (46)
Previous myocardial infarction 64 (30)
Congestive heart failure 21 (10)
Previous CEA ipsilateral 16 (8)
Previous CEA contralateral 11 (5)
Previous cerebrovascular event or TIA 109 (52)
SAPPHIRE high risk characteristics, n (%)
$1 high risk features 92 (44)
$2 high risk features 21 (10)
Carotid lesion characteristics, n (%) n = 208
Symptomatic stenosis * 92 (44)
Contralateral occlusion 25 (12)
Contralateral stenosis $ 50% 77 (37)
Reccurent stenosis after endarterectomy 14 (7)
PCI; percutaneous coronary intervention; CABG; coronary artery bypass grafting.
CEA; carotid endarterectomy; TIA, transient ischemic attack.
SAPPHIRE; Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy trial.
*TIA or CVI (cerebrovascular insult) in the preceding 6 months.
doi:10.1371/journal.pone.0035300.t001
Figure 1. Conventional angiography of the left internal carotid
artery with a severe stenosis by an 80 years old male patient.
doi:10.1371/journal.pone.0035300.g001
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routinely administered intravenously prior to balloon inflation or
stenting if no predilatation was performed. Following placement of
the protection devices procedures were usually performed with
predilation (3.5 mm to 4.5 mm), stent deployment, and postdila-
tion (5.0 mm–6.5 mm). Choice of stent was at the discretion of the
interventional physician (tapering, open versus closed cell design).
Before retrieval of the protection device, final biplane angiogram
of the stented lesion as well as intracranial views were obtained
(Fig. 3,4,5).
Outcome Measures
Follow-up consisted of CCDS and clinical examination at
1 month, 6 months, 12 months, and yearly thereafter. The
primary outcome measures were in accordance to the Stenting
and Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial. At 30 days, major adverse
events (MAE) consisted of the composite occurrence of death,
stroke, or myocardial infarction (MI). In addition, the rate of death,
any stroke or myocardial infarction at follow-up was tracked.
Minor stroke was defined as focal neurological deficit lasting more
than 24 hr with Ranking score #2 and NIH stroke score #4, while
major stroke was diagnosed in the presence of a Ranking score .3
or NIH score $15. Any rise in CK-MB or troponin or new
pathological Q-waves on ECG defined MI. Restenosis was
diagnosed in the presence of a $50% luminal narrowing as
assessed by flow velocities using CCDS [10]. Technical success was
defined by the coverage of the carotid lesion with a stent in the
presence of a residual stenosis ,50%and normal flow. Stenosis was
classified as: not significant (0–49% stenosis), moderate (50–69%),
severe (70–99%), or occluded (100%).
The peak systolic velocities of the common carotid and the
internal carotid arteries and the end diastolic velocity of the
internal carotid artery were recorded with CCDS.
Statistics
Continuous variables were expressed as the mean61 standard
deviation. Categorical data were presented as actual numbers and
percentages.
Results
Unilateral carotid artery interventions were performed in 186
patients. Target lesion revascularization was performed in one
Figure 2. Catheterizing of the left common-and internal carotid
artery and stent implantation.
doi:10.1371/journal.pone.0035300.g002
Figure 3. Stent implanted into the left internal carotid artery.
doi:10.1371/journal.pone.0035300.g003
Figure 4. Angiogram after stenting the left internal carotid
artery.
doi:10.1371/journal.pone.0035300.g004
Figure 5. Intracranial control angiogram after procedure.
doi:10.1371/journal.pone.0035300.g005
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CAS. Twenty one patients underwent bilateral staged CAS.
Detailed baseline characteristics of all patients with successful
CAS are shown in Table 1.
Mean age was 69 years with a range age from 38–88 years
(Table 1). Comorbidities were previous cardiac intervention in 100
patients (48%). This relatively high prevalence in cardiovascular
comorbidities is shown in Table 1 in relation to the SAPPHIRE
trial risk stratification with 1 or more high risk features in 54% of
the cases. One third of the patients had a symptomatic carotid
stenosis, 25 patients (12%) had a contralateral carotid artery
occlusion and 14 patients (7%) had a recurrent carotid stenosis
after CEA (Table 1).
Technical procedural success was achieved in all of the cases
(Table 2). Emboli protection devices (EPD) were used in 99% of
the procedures (included the 11 patients with balloon occlusion
devices). In 1% no EPD were used due to severe tortuosities of the
internal carotid artery. The lesions were predilated in 76% and
postdilated in 97% of all procedures. One stent per procedure was
used in 200 patients (96%). In 8 patients more than one stent were
necessary to cover the long carotid lesions. In one patient, an
additional stent was necessary to cover a dissection caused by
catheter guiding.
During the CAS procedure in 26 patients (13%) occurred an
internal carotid artery spasm which resolved either spontaneously
or after administration of intra-arterial nitro-glycerine without any
neurological complications (Table 3). Two patients had a seizure
due to longer periode of hypotension during the intervention that
spontaneously resolved. Periinterventional haemoglobin drop was
observed in five patients without any postinterventional relevant
bleeding at the access site, and most pro explainable source of
blood loss. The facts that large volume of fluid were intravenously
given during the procedure and the periinterventional blood loss
through the catheters may be the reason of these anaemia. In one
of these patients the anaemia was already known before. Seven
patients with access groin hematomas were treated conservatively
and no other access site complications were observed.
Major adverse event (MAE) rate within 30 days was 1.9%. Four
patients suffered a stroke, two nonipsilateral. Two patients suffered
an ipsilateral stroke, as the result of an air embolisation during
balloon dilatation caused by a balloon defect. The contra lateral
strokes were likely both due to periinterventional embolisation
because of guiding catheter manipulation in the aortic arch. There
were no deaths or MI within 30 days. There were 2.2% (2/92) and
0.8% (1/116) major adverse events in symptomatic and asymp-
tomatic carotid artery stenosis, respectively.
The mean follow-up was 22 months with a follow-up range
from 2–72 months. After 30 days of follow-up, 13 patients died
(6.3%), 4 suffered a stroke (1.9%) and 4 had a MI (1.9%). The
comorbidities of patients who died were: five patients with
refractory heart failure, three with cancer (prostate, stomach,
bottom lip), one who committed suicide, one with a rupture of an
aortic aneurysm, one who died as consequence of his diseases
(chronic heart- and kidney insufficiency, atrial fibrillation, and
chronic obstructive pulmonary disease), and two in absence of an
identifiable cause of death (one who suffered an intracranial
bleeding six months before death and a coronary heart disease
with chronic atrial fibrillation, six months after CAS, the other
with Diabetes mellitus type II, a mild insufficiency of the mitral
and aortal valve and a diastolic dysfunction with an ejection
fraction of 62%, 23 months after CAS).
Two MI were in patients with a known coronary heart disease,
20 respectively 40 months after CAS. One suffered a MI during
aorto-coronary bypass surgery six weeks after CAS and the fourth
Table 2. Procedural Data.
n=208
Angiographic and Doppler parameters
Mean Angiographic degree of stenosis, %
1 83
Doppler flow velocities
2
Vmax ICA systolic/diastolic, cm/sec 340/120
Vmax ICA/Vmax CCA 6
Drug regimen, n (%)
Pretreatment with aspirin and clopidogrel
3 206 (99)
Atropin administration 184 (88)
Any periprocedural norepinephrine 62 (30)
Norepinephrine boluses 56 (26)
Norepinephrine drip at end of procedure 6 (3)
Unfractionated heparin 208 (100)
Technical characteristics, n (%)
Procedural success 208 (100)
Emboli protection device use 206 (99)
Angioguard 86 (41)
Spider 19 (9)
Filterwire 59 (28)
Emboshield 33 (16)
Ballon occlusion device 11 (5)
Stents, n (%) 208 (100)
More than 1 stent 8 (4)
Type of stent
Precise 132 (63)
Acculink, Braun, Herculink, Bigsize 11 (6)
Vivexx 20 (10)
Nexstent 7 (3)
Cristallo 28 (13)
Vascuflex 10 (5)
Postdilatation, n (%) 202 (97)
1 visual estimated.
2 Vmax; maximum velocity; ICA; internal carotid artery; CCA; common carotid
artery.
3 One patient with aspirin allergy was treated periprocedurally with additional
tirofiban and discharged on clopidogrel 150 mg/day for 1 month and 75 mg/
day indefinitely.
doi:10.1371/journal.pone.0035300.t002
Table 3. Periprocedural Findings and Complications.
n=208
n( % )
Internal carotid artery spasm 26 (13)
Seizure 2 (1)
Transfusion of erythrocytes 7 (3)
Femoral pseudoaneurysm, arteriovenous
fistulas, dessection
0
Endovascular or surgical treatment of
femoral access required
0
doi:10.1371/journal.pone.0035300.t003
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detected coronary heart disease manifested with an acute
biventricular cardial decompenstation with dyspnea NYHA grade
II and a progredient angina pectoris.
The overall MAE at follow-up was 8.2% (Table 4). The overall
death or any stroke rate was 10%. The number of patients over
70 years was 65 (31%). The overall MAE rate in these patients was
13.8% (9 patients). The overall MAE rate in younger patients was
8.3% (12 patients).
A CCDS 6 months post CAS were performed by 78% of all
cases (164/208). The restenosis rate was 4.8% (9 patients with a
restenosis $50%, respectively, and one patient with a stent
occlusion). Target lesion revascularization rate was performed in
one patient only due to an asymptomatic restenosis detected in
9 months follow-up with CCDS.
Discussion
Our study demonstrates the short-and long-term safety of CAS
regarding relevant end points performs well according to current
recommendation guidelines.
All carotid stenosis could be successfully treated. In 99% of the
procedures emboli protection devices (EPD) has been used without
any complications. The benefit of EPDs has not been established
in randomized controlled trials, and available data are conflicting
[11]. In our trial the 30 days-stroke-rate by using EPDs is 1.9%,
well aware of the causes of the four periinterventional strokes: two
due to an air embolisation and two caused by guiding catheter
embolisation in the aortic arch, means probably before the EPD
could be installed.
The meta-analysis by Bonati et al [12] showed a higher risk for
stroke or death in patients older than 70 years after carotid
stenting within 120 days after randomization. In younger patients
was the risk for adverse events similar in both groups. Another
important point which was discussed in this meta-analysis was the
experience of the interventional physicians, who performed the
carotid stenting. The center recruitment rate of less than 1 patient
was a predictor of adverse events.
Economopoulos et al. [13] confirmed in their meta-analysis the
findings of Bonati et al. Another finding of this meta-analysis was
the exhibition of lower rates of strokes and the higher rates of
myocardial infarction in carotid endarterectomy than in carotid
stenting patients.
The last published and one of the most important studies about
carotid stenting, the CREST trial [14] showed no significant
difference in the risk of the composite primary outcome of stroke,
myocardial infarction or death between carotid artery stenting and
carotid endarterectomy. The incidence of periprocedural stroke
was higher in carotid stenting group than in endarterectomy
group. On the other hand the incidence of periprocedural
myocardial infarction was higher in endarterectomy group than
in the stenting group. These findings confirm the findings of the
meta-analysis by Economopoulos et al. They have an important
clinical impact in the case of treating patients with primary cardiac
disease, where the carotid stenting procedure may be preferred.
In our study the mean age of patients was 69 years. The
number of patients over 70 years was 65 (31%). The overall MAE
rate in these patients was 13.8% (9 patients). The overall MAE
rate in younger patients was 8.3% (12 patients). These data
correlate very well with the findings of both meta-analysis
mentioned above.
The periprocedural rate of myocardial infarction was 0%, and
the rate of stroke was 1.9%. These data confirm the finding of the
CREST trial about the low periprocedural risk for myocardial
infarction in carotid stenting group.
The MAE rate within 30 days was 1.9%, corresponding to four
periinterventional strokes. Compared with the periprocedural
death-and stroke-limits of 6% for symptomatic and 3% for
asymptomatic lesions, for CEA set by the American Heart
Association [15], the 30 days MAE-rate in our trial did definitively
well. A meta-analysis showed 30 days MAE-rates after CAS up to
8% [16], which illustrates the more our good result. The overall
ipsilateral stroke rate of only 1.4% and the restenosis rate of 4.8%
at follow-up demonstrates well the safety of the procedure after
long-term durability. Reported rates of early restenosis after CAS
vary widely. Newly published long-term results concerning
restenosis rate in the CAVATS study showed a three time higher
incidence of developping a restenosis of $50% in endovascular
than after endarterectomy [6]. In this trial the incidence of
restenosis rate after endovascular treatment by balloon dilatation
was significally higher than with a stent. From the 50 patients who
received a stent, 23% of them after one year and 37% after five
years, respectively, developed a restenosis of $50%, which is
definitively higher than in our trial. This trial also demonstrated,
that the greatest part of the restenosis occurred after one year
follow-up in each surgical group, means that our restenosis rate
result by a mean ultrasound follow-up of 22 months is well
representative.
No periprocedural myocardial infarction was observed, even
though cardiac heart enzymes and ECG were routinely controlled.
That confirms the findings of SAPPHIRE trial, namely that the
one-year-MAE- rate, means death, stroke and newly also MI
included, was significantly lower in CAS than in CEA group,
largely due to the higher incidence of perioperative MI in the CEA
Table 4. Major Adverse Events.
n( % )
Within 30 days 208 Patients
Death 0
Stroke 4 (1.9)
Major ipsilateral 2 (0.9)
Major nonipsilateral 1 (0.5)
Minor ipsilateral 0
Minor nonipsilateral 1 (0.5)
Myocardial infarction 0
Death, Stroke or Myocardial infarction 4 (1.9)
After 30 days 208 Patients
Death 13 (6.3)
Stroke 4 (1.9)
Major ipsilateral 0
Major nonipsilateral 0
Minor ipsilateral 1 (0.5)
Minor nonipsilateral 3 (1.4)
Myocardial infarction 4 (1.9)
Overall 208 Patients
Death, Stroke or Myocardial infarction 17 (8.2)
at 30 days plus death or ipsilateral
stroke within 31 days of follow-up
Death or any Stroke 21 (10)
Overall (death or any stroke) Patients .70 years 9 (13.8%)
doi:10.1371/journal.pone.0035300.t004
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patients with a carotid stenosis have a higher prevalence of
coronary artery disease despite the absence of cardiac symptoms
[17].
The overall MAE-rate (8.2%) according to SAPPHIRE and the
Death-or-any-Stroke-rate (10%) are at most driven by the higher
incidence of death in comparison with the other MAE-factors but
not correlating with long-term side effects or complications of
CAS. The incidence of death is not surprising considered the
mean age of 68 years and the high incidence of comorbidities.
In our institution cardiovascular events were allocated by a
neurologist, who visited the patients before and after the
intervention. An appropriate patient selection was one of the
most important points. Only Patients with an adequate anatomy
for percutaneous transcatheter approach qualified for the
intervention. In elder patients we used the distal protection to
reduce the risk of ipsilateral stroke. All these steps contributed to
the overall risk reduction and safety of CAS.
The findings of this study are limited by the fact that this was a
retrospective study. Furthermore, the study power is limited by the
relatively small study population and shorter follow-up duration.
In summary, the results of this study suggest that CAS is a safe
method for treatment of appropriate selected patients (especially
patients younger than 70 years) with carotid stenosis, with good
short-and-long-term results.
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